RPRX Quote, Financials, Valuation and Earnings

Incyte Corp. has a net margin of 72.91% compared to Royalty Pharma Plc's net margin of 31.05%. Royalty Pharma Plc's return on equity of 13.15% beat Incyte Corp.'s return on equity of 31.1%.

Royalty Pharma Plc has a consensus price target of $48.10, signalling upside risk potential of 7.72%. On the other hand Incyte Corp. has an analysts' consensus of $103.86 which suggests that it could fall by -4.18%. Given that Royalty Pharma Plc has higher upside potential than Incyte Corp., analysts believe Royalty Pharma Plc is more attractive than Incyte Corp..

Royalty Pharma Plc has a beta of 0.423, which suggesting that the stock is 57.722% less volatile than S&P 500. In comparison Incyte Corp. has a beta of 0.825, suggesting its less volatile than the S&P 500 by 17.542%.

Royalty Pharma Plc has a quarterly dividend of $0.22 per share corresponding to a yield of 1.97%. Incyte Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma Plc pays 43.94% of its earnings as a dividend. Incyte Corp. pays out -- of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma Plc quarterly revenues are $609.3M, which are smaller than Incyte Corp. quarterly revenues of $1.4B. Royalty Pharma Plc's net income of $444.2M is higher than Incyte Corp.'s net income of $424.2M. Notably, Royalty Pharma Plc's price-to-earnings ratio is 25.53x while Incyte Corp.'s PE ratio is 18.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma Plc is 10.87x versus 4.48x for Incyte Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 72.91% compared to Royalty Pharma Plc's net margin of 34.4%. Royalty Pharma Plc's return on equity of 13.15% beat Eli Lilly & Co.'s return on equity of 106.26%.

Royalty Pharma Plc has a consensus price target of $48.10, signalling upside risk potential of 7.72%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,183.22 which suggests that it could grow by 11.82%. Given that Eli Lilly & Co. has higher upside potential than Royalty Pharma Plc, analysts believe Eli Lilly & Co. is more attractive than Royalty Pharma Plc.

Royalty Pharma Plc has a beta of 0.423, which suggesting that the stock is 57.722% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Royalty Pharma Plc has a quarterly dividend of $0.22 per share corresponding to a yield of 1.97%. Eli Lilly & Co. offers a yield of 0.57% to investors and pays a quarterly dividend of $1.50 per share. Royalty Pharma Plc pays 43.94% of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma Plc quarterly revenues are $609.3M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Royalty Pharma Plc's net income of $444.2M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Royalty Pharma Plc's price-to-earnings ratio is 25.53x while Eli Lilly & Co.'s PE ratio is 46.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma Plc is 10.87x versus 14.60x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics, Inc. has a net margin of 72.91% compared to Royalty Pharma Plc's net margin of 7.53%. Royalty Pharma Plc's return on equity of 13.15% beat PTC Therapeutics, Inc.'s return on equity of --.

Royalty Pharma Plc has a consensus price target of $48.10, signalling upside risk potential of 7.72%. On the other hand PTC Therapeutics, Inc. has an analysts' consensus of $88.50 which suggests that it could grow by 18.51%. Given that PTC Therapeutics, Inc. has higher upside potential than Royalty Pharma Plc, analysts believe PTC Therapeutics, Inc. is more attractive than Royalty Pharma Plc.

Royalty Pharma Plc has a beta of 0.423, which suggesting that the stock is 57.722% less volatile than S&P 500. In comparison PTC Therapeutics, Inc. has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.641%.

Royalty Pharma Plc has a quarterly dividend of $0.22 per share corresponding to a yield of 1.97%. PTC Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma Plc pays 43.94% of its earnings as a dividend. PTC Therapeutics, Inc. pays out -- of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma Plc quarterly revenues are $609.3M, which are larger than PTC Therapeutics, Inc. quarterly revenues of $211M. Royalty Pharma Plc's net income of $444.2M is higher than PTC Therapeutics, Inc.'s net income of $15.9M. Notably, Royalty Pharma Plc's price-to-earnings ratio is 25.53x while PTC Therapeutics, Inc.'s PE ratio is 8.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma Plc is 10.87x versus 3.45x for PTC Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ultragenyx Pharmaceutical, Inc. has a net margin of 72.91% compared to Royalty Pharma Plc's net margin of -112.81%. Royalty Pharma Plc's return on equity of 13.15% beat Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83%.

Royalty Pharma Plc has a consensus price target of $48.10, signalling upside risk potential of 7.72%. On the other hand Ultragenyx Pharmaceutical, Inc. has an analysts' consensus of $64.00 which suggests that it could grow by 159.11%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Royalty Pharma Plc, analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Royalty Pharma Plc.

Royalty Pharma Plc has a beta of 0.423, which suggesting that the stock is 57.722% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical, Inc. has a beta of 0.161, suggesting its less volatile than the S&P 500 by 83.893%.

Royalty Pharma Plc has a quarterly dividend of $0.22 per share corresponding to a yield of 1.97%. Ultragenyx Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma Plc pays 43.94% of its earnings as a dividend. Ultragenyx Pharmaceutical, Inc. pays out -- of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma Plc quarterly revenues are $609.3M, which are larger than Ultragenyx Pharmaceutical, Inc. quarterly revenues of $159.9M. Royalty Pharma Plc's net income of $444.2M is higher than Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M. Notably, Royalty Pharma Plc's price-to-earnings ratio is 25.53x while Ultragenyx Pharmaceutical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma Plc is 10.87x versus 3.82x for Ultragenyx Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.